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Conventionally, the assessments of endothelial function and arterial stiﬀness require diﬀerent sets of equipment, making the
inclusion of both tests impractical for clinical and epidemiological studies. Pulse wave analysis (PWA) provides useful information
regarding the mechanical properties of the arterial tree and can also be used to assess endothelial function. PWA is a simple, valid,
reliable, and inexpensive technique, oﬀering great clinical and epidemiological potential. The current paper will outline how to
measure arterial stiﬀness and endothelial function using this technique and include discussion of validity and reliability.
1.Introduction
Cardiovasculardisease(CVD),theleadingcauseofmortality
in the Western world [1], has a very long asymptomatic
phase of development, starting as early as the ﬁrst decade
of life [2]. It is imperative, therefore, that clinical scientists
and epidemiologists have at their disposal simple, valid,
and reliable techniques to assess and track the progression
of CVD. Noninvasive assessment techniques fall under two
broad categories: those that assess endothelial health and
those that assess arterial stiﬀness. Assessment of endothelial
function indicates the functional health of the vascular sys-
tem, whereas arterial stiﬀness assesses structural characteris-
tics. Together, these techniques may provide complimentary
indices of CVD risk.
Conventionally, assessments of endothelial function and
arterial stiﬀness require diﬀerent sets of equipment, making
the inclusion of both tests impractical for clinical and
epidemiological studies. Pulse wave analysis (PWA) is a
simple and noninvasive technique that has been widely
used in epidemiological [3] and interventional studies [4].
PWA provides useful information regarding the mechanical
properties of the arterial tree and the ventricular-vascular
interaction [5] and can also be used to assess endothelial
function[6].PWAisasimple,valid,reliable,andinexpensive
technique, oﬀering great clinical and epidemiological poten-
tial. The current review will outline how to measure arterial
stiﬀness and endothelial function using this technique and
include discussion of validity and reliability.
2. ArterialStiffness
Arterial stiﬀness is a general term that collectively describes
distensiblility,compliance,andelasticmodulusofthearterial
vascular system. These properties are not homogenous along
the arterial tree and muscular and elastic vessels diﬀer.
Arterial stiﬀn e s sc a nb em e a s u r e ds y s t e m i c a l l y ,r e g i o n a l l y ,o r
locally.Local measurementsprovide important physiological
information and are more quantitative and sensitive than
systemic indices. However, these measurements give no
indication of how the artery of interest interacts with central
function (i.e., the heart) as part of an integrative system.
Regional arterial stiﬀness is measured at arterial sites of
major physiologic importance such as the aorta where the
arterial buﬀering function is principally expressed, or a
particular limb. Systemic arterial stiﬀness aﬀects the global
buﬀering properties of the arterial system, just as arterial2 International Journal of Vascular Medicine
blood pressure can be considered as a global value of
hemodynamic load, systemic arterial stiﬀness reﬂects the
overall opposition of large arteries to the pulsatile eﬀects of
ventricular ejection.
A number of methodologies have been applied to the
in vivo assessment of arterial stiﬀness. These methodologies
fall into three broad groups: (1) relating change in area
of an artery to distending pressure, that is, local arterial
stiﬀness, (2) measuring pulse wave velocity, that is, regional
arterial stiﬀness, and (3) pulse wave analysis, that is, systemic
arterial stiﬀness. Ultrasound and magnetic resonance
imaging (MRI) are capable of measuring local arterial
stiﬀness [21–23] as well as pulse wave velocity [24–30],
but these methodologies require expensive equipment
(especially in the case of MRI) and a high level of technical
expertise and are often impractical within the clinical or
epidemiological setting. PWV can also be assessed using
dedicated equipment, including oscillometric [31–34],
tonometric [32, 35–37], volume plethysmographic [38, 39],
and photo plethysmographic [40–43] devices. These devices
either measure the pulse wave at two peripheral sites or
record the electrocardiogram and measure the pulse wave
at a peripheral site, to estimate the regional arterial stiﬀness.
Alternatively, a number of devices are also available to
estimate systemic arterial stiﬀness using PWA.
2.1. Measurement. A number of commercial devices are
available to automate PWA assessments, including Compi-
lor (tonometric device) [44, 45], Sphygmocor (tonometric
device) [44, 46–49], PulsePen (tonometric device) [50, 51],
ARCSolver [47, 52] (oscillometric device), Arteriograph
[33, 53–57] (oscillometric device), Omron (oscillometric
device) [55, 58], PulseCore [59, 60]( o s c i l l o m e t r i cd e v i c e ) ,
Viscorder [32, 34, 49]( o s c i l l o m e t r i cd e v i c e ) ,a n dP u l s e T r a c e
[6, 42, 48, 61] (photoplethysmographic device). Applanation
tonometry is considered the “gold standard” and is the most
widely used technique [62]. A probe is conventionally placed
ontheskinoverlyingtheradialartery,andpressureisapplied
to distort or applanate (ﬂatten) the artery, creating a signal
which approximates arterial pressure. The peak and trough
of the radial pulse wave correspond, respectively, to systolic
and diastolic blood pressure measured conventionally on the
brachial artery, since blood pressure is practically identical
in brachial and radial arteries [63]. Mean blood pressure is
determined by integration of the radial wave. A generalized
transfer factor is then used to generate the corresponding
central arterial waveform [64–67].
Figure 1 shows typical features of the aortic pulse pres-
sure waveform, from which can be derived augmentation
pressure (AP), augmentation index (AIx), and arrival time
of reﬂected waves at the central aorta (Tr). Tr represents
the time from the onset of the ejected pulse waveform to
the onset of the reﬂected wave and reﬂects aortic pulse
wave velocity [68]. AP is the additional aortic systolic
pressure generated by the return of the reﬂected waves at
the central aorta, expressed in absolute terms [62]. AIx is
the AP as a percentage of central pulse pressure and is a
composite measure of aortic wave reﬂection and systemic
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Figure 1: Aortic pulse pressure waveform. Systolic and diastolic
pressures are the peak and trough of the waveform. Augmentation
pressure is the additional pressure added to the forward wave by the
reﬂected wave. Augmentation index is deﬁned as the augmentation
pressure as a percentage of pulse pressure. The dicrotic notch
representsclosureoftheaorticvalveandisusedtocalculateejection
duration. Time to reﬂection is calculated as the time at the onset of
the ejected pulse waveform to the onset of the reﬂected wave.
Figure 2:Electronicsmodule(SphygmoCordevice,AtCorMedical,
Sydney, Australia).
arterialstiﬀness[62,69].Althoughthetimingofthearrivalof
the reﬂected wave at the proximal aorta is largely determined
by large artery PWV, AIx is not interchangeable with PWV.
It is inﬂuenced by vasoactive drugs independently of PWV
[70], suggesting that it is also determined by the intensity
of wave reﬂection, which, in turn, is determined by the
diameter and elasticity of small arteries and arterioles.
A number of variables are known to inﬂuence AIx. AIx
increases with MAP [71] and is inversely related to body
height [72] and heart rate [73, 74], with a 10bpm increase
in heart rate resulting in a 4% reduction in AIx [73].
AIx should be normalized for a heart rate of 75 beats per
minute (AIx@HR75). One of the most widely used devices,
SphygmoCor, automatically adjusts the AIx at an inverse rate
of 4.8% for each 10bpm increment. The AIx@HR75 is only
calculated when the patient’s heart rate is between 40 and
110bpm. Outside of this range the software will display an
N/C indicating that no calculation was possible.
Using the SphygmoCor to illustrate the procedure (a
typicalsetupisshowninFigure 2),PWAtakesapproximately
20 minutes to complete. Following at least 10 minutes supine
rest, brachial artery systolic and diastolic blood pressures are
measured in the nondominant arm and used to calibrateInternational Journal of Vascular Medicine 3
the PWA measurements taken on the radial artery. Radial
artery waveforms are then recorded in duplicate. A high-
ﬁdelity tonometer is used to obtain pressure waveforms
by applying gentle pressure over the nondominant radial
artery and repositioning the device until the greatest pulse
signal is detected. Data is collected directly into a personal
computer, and recordings are assessed visually to ensure that
the best possible recording is obtained. After 20 sequential
waveforms are acquired, an averaged peripheral waveform is
generated and a corresponding aortic waveform is derived
(see Figure 3). When consecutive AIx@HR75 readings diﬀer
by more than 4%, a third reading is obtained, and the mean
of the closest two readings is taken.
2.2. Validity. There is evidence that increased aortic wave
reﬂections have adverse eﬀects on ventricular afterload and
coronary perfusion, and their pathological role has been
demonstrated in several diseases [75–78]. Furthermore,
increased central arterial wave reﬂections have been shown
to independently predict cardiovascular risk and mortality
[5, 79, 80]. Increased amplitude and the earlier return of
the reﬂected wave within the cardiac cycle augments the
central systolic blood pressure, resulting in increased wave
reﬂections [69]. The amplitude and timing of reﬂected pres-
sure waves are determined primarily by vascular elasticity,
peripheral vascular resistance, heart rate, and left ventricle
function [81].
2.3. Reliability. Any valid technique utilised for the mea-
surement of physiological variables must be reproducible
[82]. A high intra- and interobserver reproducibility of
baseline AIx has been observed in healthy controls and
patients with cardiovascular disease and renal dysfunction
[7, 38, 82–94]. Good reproducibility of baseline time to
reﬂection (Tr),analternativeindextoAIx,hasbeenreported
in several studies [88, 91, 94]. However, the majority of
these trials examined the reproducibility using simple Bland-
Altman analysis, whereas studies using more deﬁnitive intra-
class correlation coeﬃcient (ICC) and the contribution of
variance components are limited [81, 82, 91, 93, 94]. ICC
values for repeated measurements taken at hourly or weekly
intervals have been reported to be 0.72–0.90 for AIx [91, 94],
0.90 for AP [81], and 0.43–0.84 for Tr[ 81, 91, 94]. In
addition, few trials have reported the reproducibility of heart
rate corrected AIx [82, 91, 93], although it is frequently used
in wave reﬂection studies. While this technique potentially
oﬀers a valid and reliable marker of CVD risk, further study
is required to determine sample size recommendations for
AIx normalized to heart rate.
2.4. Recommendations. The PWA technique is particularly
suitable for incorporation into clinical trials. Strengths of
this technique include simplicity of assessment, relatively
short training requirements for investigators, low time
commitment for subjects, noninvasiveness, portability, and
cost-eﬀectiveness. Both AIx and AP confer similar repro-
ducibility and have been reported as more reliable than Tr.
Since AIx is strongly inﬂuenced by heart rate, both AIx
Figure 3: Radial artery applanation tonometry recording. The
upper long panel shows the radial pressure waveform above the
derived central pressure waveform. The upper right panel shows
the overlaid radial waveforms, including the operator index, and
the middle panel shows the quality control indices. The bottom left
panel demonstrates a magniﬁed radial arterial waveform. Systolic
and diastolic pressures are 145/92mmHg. The bottom right panel
provides a magniﬁed derived central pressure waveform. Central
pressure is 137/93mmHg.
and AP should be corrected for this confounding factor
[73]. Further study is warranted to determine whether the
three indices of arterial stiﬀness provide additive prognostic
value.
3.EndothelialHealth
Functionally, the endothelium is a largeautocrine, paracrine,
and endocrine organ that plays a key role in vascular
homeostasis [95]. Endothelial dysfunction is a pivotal, yet
potentially reversible, step that has been shown to precede
and predict overt CVD [96]. The endothelium has been
recognized for the important role it plays in regulating
vascular reactivity via the release of dilator mediators,
including nitric oxide (NO) [97–100], prostaglandins [101],
and endothelial-derived hyperpolarizing factor [102, 103].
The capacity of the endothelium to regulate vascular tone
(reactivity)isusedtoconﬁrmthehealthoftheendothelium.
Established methodologies for evaluating peripheral
endothelial function include strain-gauge venous occlusion
forearm plethysmography [104, 105], ultrasound-measured
ﬂow-mediateddilation(FMD)[105–107],peripheralarterial
tonometry (e.g., using the EndoPat device) [105], and
laser Doppler ﬂowmetry [105]. These techniques assess
the vasodilator responses to endothelium-dependent stimuli
such as acetylcholine and increased shear stress and to
endothelium-independent stimuli, including sodium nitro-
prusside and glyceryl trinitrate (GTN). The two most com-
monly used techniques are strain-gauge plethysmography
and FMD, with FMD being considered the “gold standard”
for assessing endothelial function. FMD is a noninvasive,
valid [10–13], and moderately reliable [14, 15] technique
but is expensive and highly technical (Table 1). Strain-gauge
plethysmography also oﬀers acceptable reliability [17–20]
but is an invasive technique when coupled with intra-
arterial infusion of vasodilators (Table 1). As such, these
techniques are often impractical for use in clinical trials or4 International Journal of Vascular Medicine
Table 1: Comparison of noninvasive techniques for assessing endothelial function.
Technique Equipment Cost Skill level Test time Validity Reliability Ref
PWA Applanation
tonometry
Medium
US$15,000 Low 35mins Medium∗ Medium-high∗
d = 0.9–2.3% [6–9]
FMD (i) Ultrasound
(ii) Tourniquet
High
>US$50,000 High 20mins High Medium
CV: 14–50% [10–16]
Plethysmography Strain-gauge Low
US$10,000 Med. 30mins Medium Medium
CV: 8–27% [17–20]
FMD: ﬂow-mediated dilation; CV: coeﬃcient of variation; d: sample bias (mean diﬀerence); PWA: pulse wave analysis. ∗Further study is needed to corroborate
these ﬁndings.
epidemiological studies. Alternatively, a limited number of
studies have used PWA to assess endothelial function.
3.1. Measurement. Endothelial function can be assessed
noninvasively by evaluating the eﬀects of inhaled salbutamol
on the AIx [6–8]. AIx is a measure of systemic arterial
stiﬀness [62]. Notably, NO, considered the central molecule
governing endothelial function [97–100], is a key modulator
of arterial stiﬀness [108]. Chowienczyk et al. [6]d e m o n -
strated that salbutamol, a β2 agonist and endothelium-
dependent vasodilator, in part reduces wave reﬂection by
activation of the L-arginine-NO pathway.
The test takes approximately 35 minutes to complete;
following at least 10 minutes supine rest, baseline PWA is
recorded as described above, and PWA recordings are then
repeated after 5, 10, 15, and 20 minutes after the adminis-
tration of 400μg inhaled salbutamol. The maximal decrease
in AIx from baseline following a salbutamol challenge is
used as an index of endothelial function. Endothelium-
independent function can also be assessed using PWA by
measurement of the reduction in AIx following sublingual
GTN administration.
3.2. Validity. Wilkinson et al. [7] and Hayward et al. [8]
evaluated the eﬀects of inhaled salbutamol and sublingual
GTN on the AIx. Investigators observed a signiﬁcant corre-
lation between the salbutamol-mediated reductions in AIx
and increase in forearm blood ﬂow during infusion of
acetylcholine that was abolished by coadministration of NG-
monomethyl-L-arginine (L-NMMA), an endothelial NO
synthase inhibitor, suggesting that this may represent a valid
approach for assessing endothelial function. Conversely,
coadministration of intravenous L-NMMA has no inﬂuence
on sublingual GTN-mediated reductions in AIx, consistent
with an endothelium-independent eﬀect [37, 74]. To date,
relatively few clinical studies have employed PWA to assess
endothelial function. However, preliminary validation stud-
ies have demonstrated blunted AIx responses to salbutamol
in subjects exhibiting diabetes [6], hypercholesterolaemia
[7], coronary artery disease [8], and peripheral vascular
disease [9] among others.
3.3. Reliability. Studies examining the reproducibility of
salbutamol-mediated eﬀects on AIx are limited [7, 8, 82].
Hayward et al. [8] assessed reliability in healthy sub-
jects using Bland-Altman analysis and reported excellent
between-day mean diﬀerence (d = 0.9 ± 2%). Wilkinson et
al.[7]alsoassessedreliabilityinhealthysubjectsusingBland-
Altman analysis and reported similar ﬁndings; between-
day mean diﬀerence in the AIx response was −2.3 ±
3.0 for salbutamol-mediated changes and 0.2 ± 6.5f o r
glyceryl trinitrate (GTN)-mediated changes. More recently,
Paul et al. [82] produced discrepant ﬁndings when they
assessed within-day reliability using the more deﬁnitive
ICC method [109]. Relatively low reliability was reported
for control (ICC: 0.18) and chronic heart failure groups
(CHF) (ICC: 0.04). However, relatively low reliability was
also reported for GTN-mediated changes in AIx for both
control(ICC:0.58)andCHFgroups(ICC:0.17).Endothelial
function assessments were repeated at hourly intervals, and
the authors suggest that the low ICC values may reﬂect
diurnal variability or a carryover eﬀect from the ﬁrst
assessment. Further study is warranted to determine the
reliability and sample size requirements for this promising
technique.
3.4. Recommendations. Salbutamol-mediated eﬀects on AIx
can be used to estimate endothelial function. This technique
oﬀers a number of advantages, namely simplicity of assess-
ment,relativelyshorttrainingrequirementsforinvestigators,
low time requirement, portability, cost-eﬀectiveness, ease of
use, good reliability indicated by preliminary studies, and
thesalbutamolchallengeisolatingtheNOpathway.However,
more clinical studies are required to further validate this
test. Also, while NO is unarguably an important molecule
governing endothelial function, the endothelium can release
additionalcomplimentaryorcompensatorymolecules[110],
most notably prostacyclin [101] and endothelial-derived
hyperpolarizing factor [102, 103]. The relative importance
of these molecules varies by vascular bed and between
individuals, particularly between individuals exhibiting a
number of diseased states [111–120]. Therefore, while this
test can provide a snapshot of endothelial function it may
notprovideacompletepicture.Furtherstudyiswarrantedto
determine whether baseline AIx (systemic arterial stiﬀness)
and AIx following salbutamol inhalation confer additive
prognostic value. Further study is also required to clarify
sample size recommendations for this test.International Journal of Vascular Medicine 5
4. Conclusion
PWA is a simple technique capable of assessing systemic
arterial stiﬀness and endothelial function. This test is
particularly suitable for clinical and epidemiological studies.
Further study is required to determine: (1) sample size
requirements,and(2)whetherbaselineAIx(systemicarterial
stiﬀness) and AIx following salbutamol inhalation confer
additive prognostic value.
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